TrianglePembrolizumab (NCT05766371)
Pembrolizumab trial for Castrate Resistant Prostate Cancer (NCT05766371). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic castration-resistant prostate cancer after progression on an androgen-signaling inhibitor. PSMA PET must show qualifying uptake, without specified PSMA-negative lesions. Prior PSMA radiotherapy or checkpoint immunotherapy is excluded.
The idea: combine PSMA-targeted radiation with pembrolizumab, which releases an immune brake. Both are infused. Two lutetium-177 PSMA-617 doses precede PSA-guided dosing, up to six total. Testosterone suppression continues; biopsy is required if safely accessible. Researchers track progression.
This phase 2 study plans 48 patients. UCSF’s Rahul Aggarwal leads it in San Francisco, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.